Filana Therapeutics (FLNA) Non Operating Interest Expenses (2022 - 2026)

Filana Therapeutics has reported Non Operating Interest Expenses for 5 years, with the latest figure at $164000.0 in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 5.13% year-over-year to $164000.0 in Q2 2026; TTM through Jun 2026 was $732000.0, a 2.14% decrease from a year earlier, with the FY2025 full-year figure at $985000.0, down 26.49% from the prior year.
• Non Operating Interest Expenses was $164000.0 for Q2 2026 at Filana Therapeutics, down from $206000.0 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $430000.0 in Q4 2022, with the low at $132000.0 in Q4 2025.
• Average Non Operating Interest Expenses over 5 years is $265277.8, with a median of $236500.0 recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses advanced 18.39% in 2023, then plunged 49.15% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $430000.0 in 2022, then plunged by 31.86% to $293000.0 in 2023, then slumped by 49.15% to $149000.0 in 2024, then declined by 11.41% to $132000.0 in 2025, then increased by 24.24% to $164000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $164000.0 (Q2 2026), $206000.0 (Q1 2026), and $132000.0 (Q4 2025), per Business Quant data.